Previous study have demonstrated that combination of miRNA and siRNA-based treatment could afford improved dual inhibition of a target protein.37 George Calin and his colleagues reported that dual targeting of EphA2 using siRNA-EphA2 and miR-520d-3p exhibits synergistic inhibition of EphA2 and significantly augments tumor regression compared to either monotherapy alone both in vitro and in vivo.38 In this study, co-treatment with miR-451 mimics and YWHAZ-siRNA significantly enhanced YWHAZ knockdown in both SKBR3/PR and MCF-7/PR cells. Here, EPHA2 is linked to neoplasm.